Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-&bgr; tyrosine kinase inhibitor, in patients with recurrent glioblastoma
暂无分享,去创建一个
P. Wen | T. Batchelor | E. Gerstner | J. Supko | S. Grossman | G. Lesser | S. Desideri | X. Ye | D. Duda | D. Peereboom | S. Chowdhary | Daniel G. Duda